Atherosclerotic plaque reduction: Blood pressure, dyslipidemia, atherothrombosis

Drugs of Today

Volumn 44, Issue 9, 2008, Pages 711-718

  Arora, Satish ^a   Nicholls, Stephen J ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CORONARY RISK; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; REVIEW; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; RISK FACTORS; THROMBOSIS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 57649128408     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.9.1263999     Document Type: Review

References (38)

1. Sever, P.S., Dahlof, B., Poulter, N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003, 361(9364): 1149-58.
2. Law, M.R., Wald, N.J., Rudnicka, A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003, 326(7404): 1423.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934): 1383-9.
4. Sacks, F.M., Moye, L.A., Davis, B.R. et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998, 97(15): 1446-52.
5. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997, 18(10): 1569-82.
6. Danchin, N., Hanania, G., Grenier, O. et al. Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys. Ann Cardiol Angeiol (Paris) 2003, 52(1): 1-6.
7. Mintz, G.S., Nissen, S.E., Anderson, W.D. et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37(5): 1478-92.
8. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291(9): 1071-80.
9. von Birgelen C., Hartmann, M., Mintz, G.S., Baumgart, D., Schmermund, A., Erbel, R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (≥12 months) follow-up intravascular ultrasound. Circulation 2003, 108(22): 2757-62.
10. Ridker, P.M., Cannon, C.P., Morrow, D. et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352(1): 20-8.
11. Albert, M.A., Danielson, E., Rifai, N., Ridker, P.M. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001, 286(1), 64-70.
12. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352(1): 29-38.
13. Nissen, S.E., Nicholls, S.J., Sipahi, I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006, 295(13): 1556-65.
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285(19): 2486-97.
15. LaRosa, J.C., Grundy, S.M., Waters, D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352 (14): 1425-35.
16. Shepherd, J., Barter, P., Carmena, R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006, 29(6): 1220-6.
17. Pedersen, T.R., Faergeman, O., Kastelein, J.J. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005, 294(19): 2437-45.
18. Assmann, G., Schulte, H., von, E.A., Huang, Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124(Suppl. 1): S11-20.
19. Yu, S., Yarnell, J.W., Sweetnam, P., Bolton, C.H. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 2003, 166(2): 331-8.
20. Luc, G., Bard, J.M., Ferrieres, J. et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002, 22(7): 1155-61.
21. Nissen, S.E., Tsunoda, T., Tuzcu, E.M. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003, 290(17): 2292-300.
22. Tardif, J.C., Gregoire, J., L'Allier, P.L. et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 2007, 297(15): 1675-82.
23. Zhang, B., Fan, P., Shimoji, E. et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 2004, 24(10): 1910-5.
24. Shimoji, E., Zhang, B., Fan, P., Saku, K. Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis 2004, 172(2): 247-57.
25. Nissen, S.E., Tardif, J.C., Nicholls, S.J. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356(13): 1304-16.
26. Kastelein, J.J., van Leuven, S.I., Burgess, L. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356(16): 1620-30.
27. Rudel, L.L., Lee, R.G., Parini, P. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2005, 25(6): 1112-8.
28. Tardif, J.C., Gregoire, J., L'Allier, P.L. et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004, 110(21): 3372-7.
29. Nissen, S.E., Tuzcu, E.M., Brewer, H.B. et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354(12): 1253-63.
30. Nissen, S.E., Tuzcu, E.M., Libby, P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004, 292(18): 2217-25.
31. Sipahi, I., Tuzcu, E.M., Schoenhagen, P. et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006, 48(4): 833-8.
32. Taylor, D.O., Edwards, L.B., Boucek, M.M. et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005, 24(8): 945-55.
33. Bae, J.H., Rihal, C.S., Edwards, B.S. et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 2006, 82 (8): 1108-11.
34. Tuzcu, E.M., Kapadia, S.R., Sachar, R. et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005, 45(9): 1538-42.
35. Eisen, H.J., Tuzcu, E.M., Dorent, R. et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349(9): 847-58.
36. Nasu, K., Tsuchikane, E., Katoh, O. et al. Accuracy of in vivo coronary plaque morphology assessment: A validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006, 47(12): 2405-12.
37. Nair, A., Kuban, B.D., Tuzcu, E.M., Schoenhagen, P., Nissen, S.E., Vince, D.G. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106(17): 2200-6.
38. Kawasaki, M., Sano, K., Okubo, M. et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2005, 45(12): 1946-53.